UK-based company that deals with AI-powered early lung disease diagnosis and precision care Optellum announced on Friday that it has achieved ISO 27001:2022 certification.
The certification is claimed to underscore the company's commitment to best practices in information security and robust data protection.
Optellum's CEO, Dr Johnathan Watkins, said, 'As a healthcare technology company, protection of the assets and data of our customers, partners, and employees is non-negotiable. I would like to congratulate our exceptional staff, in particular Massoud and our Information Security team. Their dedication and expertise have made this achievement possible.'
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Roche expands AI capabilities in cancer diagnostics
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement